Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad35-ENV
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Ad35-ENV is a recombinant, replication-defective adenovirus serotype 35 (Ad35) viral vector vaccine developed for the prevention of HIV infection. Created through a collaboration between the International AIDS Vaccine Initiative (IAVI) and Janssen (a subsidiary of Johnson & Johnson), the vaccine utilizes Janssen's proprietary AdVac technology. The vector is engineered to carry and express the envelope (env) genes derived from HIV-1 subtype A isolates. Its primary mechanism of action is to induce HIV-specific cellular and humoral immune responses against the HIV envelope protein. In clinical development, Ad35-ENV has been evaluated in Phase 1 trials, often administered as part of a heterologous prime-boost regimen in combination with other viral vectors, such as Ad26.ENVA.01, to enhance immunogenicity.
- Other names
- Ad35-ENV HIV vaccineAd-35-ENV HIV vaccineAd 35-ENV HIV vaccineRecombinant adenovirus serotype 35 HIV-1 vaccine
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on Ad35-ENV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad35-ENV.